Status:
COMPLETED
Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients
Lead Sponsor:
University of Kansas Medical Center
Conditions:
Polycystic Kidney Diseases
Eligibility:
All Genders
18-65 years
Phase:
EARLY_PHASE1
Brief Summary
The purpose of this study is to find a protein (ex. Polycystin 1 or mucin and cadherin like protein) in the urine that is changed after treatment of hydralazine.
Eligibility Criteria
Inclusion
- Confirmed diagnosis of ADPKD
- estimated glomerular filtration rate (eGFR) \> 60 ml/min/1.73m\^2
Exclusion
- History of systemic lupus erythematous or other rheumatologic disorder
- Baseline anti-nuclear antibody (ANA) \>1:80 for females and \>1:40 for males
- Blood pressure \< 120/80 without anti-hypertensive
- Angina pectoris or myocardial infarction in the last 6 months
- Liver disease
- Allergy to hydralazine
Key Trial Info
Start Date :
April 23 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 30 2020
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT03423810
Start Date
April 23 2018
End Date
January 30 2020
Last Update
February 26 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160